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ARTICLE
Inhibition of glucose metabolism selectively targets
autoreactive follicular helper T cells
Seung-Chul Choi 1, Anton A. Titov 1, Georges Abboud1, Howard R. Seay 1, Todd M. Brusko 1,
Derry C. Roopenian2, Shahram Salek-Ardakani1 & Laurence Morel1
Follicular helper T (TFH) cells are expanded in systemic lupus erythematosus, where they are
required to produce high affinity autoantibodies. Eliminating TFH cells would, however
compromise the production of protective antibodies against viral and bacterial pathogens.
Here we show that inhibiting glucose metabolism results in a drastic reduction of the fre-
quency and number of TFH cells in lupus-prone mice. However, this inhibition has little effect
on the production of T-cell-dependent antibodies following immunization with an exogenous
antigen or on the frequency of virus-specific TFH cells induced by infection with influenza. In
contrast, glutaminolysis inhibition reduces both immunization-induced and autoimmune TFH
cells and humoral responses. Solute transporter gene signature suggests different glucose
and amino acid fluxes between autoimmune TFH cells and exogenous antigen-specific TFH
cells. Thus, blocking glucose metabolism may provide an effective therapeutic approach to
treat systemic autoimmunity by eliminating autoreactive TFH cells while preserving protective
immunity against pathogens.
DOI: 10.1038/s41467-018-06686-0 OPEN
1 Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, 1395 Center Drive, Gainesville, FL 32610, USA. 2 The Jackson
Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA. Correspondence and requests for materials should be addressed to L.M. (email: morel@ufl.edu)
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The germinal center (GC) is the primary site of clonalexpansion and affinity maturation for B cells throughsurvival and selection signals provided by follicular helper
CD4+ T (TFH) cells. GC-derived plasma cells produce high-
affinity antibodies against pathogens or autoantigens1. Control-
ling TFH cell numbers is essential for the optimal affinity
maturation in GC response: an insufficient TFH generation
underlies impaired humoral immune responses in primary
immunodeficiencies, while excessive generation of TFH cells
allows the survival of low-affinity self-reactive clones, resulting in
the production of autoantibodies2. Systemic lupus erythematosus
(SLE) is characterized by class-switched high-affinity auto-
antibodies, indicating GC involvement3. The frequency of TFH
cells is expanded in all spontaneous mouse models of lupus and a
high frequency of circulating TFH cells has been reported in
multiple cohorts of SLE patients, which often correlated with
disease severity4. Accordingly, interrupting TFH cell differentia-
tion by blocking CD40-CD40L interactions5,6 or IL-217–10 sig-
naling, or by delivering miR-146a11, improved disease outcomes
in lupus-prone mice. Moreover, several drugs that have promis-
ing results in SLE patients reduce the number of circulating TFH
cells12–15.
The cytokines and transcription factors that regulate T cell
differentiation reprogram the metabolism of naive CD4+ T cells
into effector subset-specific metabolic profiles, which provide
regulatory checkpoints to fine-tune T cell differentiation and
function16. CD4+ T cells of lupus patients17 and mouse models of
lupus18 present metabolic alterations, which include high mTOR
complex 1 (mTORC1) activity, glycolysis and oxidative metabo-
lism. In the B6.Sle1.Sle2.Sle3 (TC for triple congenic) model of
lupus that shares more than 95% of its genome with the congenic
C57BL/6 (B6) controls19, inhibiting glycolysis with 2-
deoxyglucose (2DG) and the mitochondrial electron transport
chain with metformin normalizes T cell metabolism and reverses
autoimmune pathology20. These findings were confirmed in
NZB/W F1 and B6.lpr mice, two other models of lupus20,21.
Importantly, the frequency and number of TFH cells as well as GC
B cells were normalized by this dual treatment, suggesting the
autoreactive expansion of TFH cells was dependent on either
glycolysis or mitochondrial metabolism, or a combination of the
two.
The understanding of the metabolic requirements of TFH cells
has been lagging comparatively to other CD4+ T cell effector
subsets. TFH cells induced by LCMV Armstrong viral infection
are metabolically quiescent as compared to TH1 cells22, with a low
PI3K-AKT-mTORC1 activation and an overall decreased mito-
chondrial and glucose metabolisms. These results are consistent
with the findings that Bcl623 and PD-124, both highly expressed
by TFH cells, independently inhibit cellular metabolism including
glycolysis in vitro. However, gene targeting showed that mTOR
activation is required for homeostatic and immunization-induced
TFH differentiation in vivo25,26 by enhancing glycolysis26. More-
over, mTORC1 activation is associated to autoreactive TFH cell
expansion by promoting the translation of Bcl6, the master reg-
ulator of TFH cell gene expression, in the Def6tr/trSwap70−/−
DKO mice27. In the framework of these results obtained in dif-
ferent models with different approaches, the specific metabolic
requirements of spontaneous lupus TFH cells to expand have not
been characterized, and it is unclear whether they are similar to
the metabolic requirements of TFH cells that are induced by
exogenous antigens.
Here, we show that the inhibition of glycolysis reduces the
expansion of autoreactive TFH cells in four lupus-prone models,
but it has little effect on the production of T-dependent (TD)
antigen (ag)-specific antibodies, or the production of influenza-
specific TFH cells in either non-autoimmune B6 or lupus-prone
TC mice. In addition, spontaneous lupus TFH but not virus-
specific TFH cells express low levels of amino acid transporters as
compared to B6 TFH cells. Accordingly, glutaminolysis inhibition
with the glutamine analog 6-Diazo-5-oxo-L-norleucine (DON)
prevents the production of TD Ag-specific antibodies, and
impairs spontaneous GCs. Overall, this study showed that high
glucose utilization is a unique requirement of autoreactive TFH
cells, whereas glutamine metabolism is used by all TFH cells.
These opposite metabolic programs suggest that autoreactive and
Ag-specific TFH cells are driven by different mechanisms, and
imply that inhibiting glycolysis can uniquely target pathogenic
autoreactive TFH cells while preserving protective immunity
against pathogens.
Results
Expanded spontaneous TFH population in lupus mice. CD4+
T cells from anti-dsDNA IgG-producing lupus-prone TC mice
showed an increased expression of the early activation marker
CD69, as well as an accumulation of effector memory T (TEM)
and TFH cells (Fig. 1a–c) as compared to B6 controls. Lupus mice
also showed a decreased frequency of CXCXR5+PD1+Bcl6
+Foxp3+ TFR relative to TFH cells (Fig. 1c). Similar results were
obtained in young TC mice before the production of anti-dsDNA
IgG (Supplementary Fig. 1a-d), indicating that CD4+ T cell
activation and the expansion of TEM and TFH CD4+ T cells
precedes the manifestation of autoimmunity. mTORC1 activity
measured by phosphorylation of ribosomal protein S6 (pS6) was
increased in total TC CD4+ T cells20. Here, pS6 expression was
increased in naive CD4+ T cells (TN, CD4+CD44−) and TFH
(CD4+CD44+PD-1hiPSGL-1lo) cells from autoantibody produ-
cing and pre-autoimmune TC as compared with B6 mice (Fig. 1d
and Supplementary Fig. 1e). The increased mTORC1 activation
in CD44-negative CD4+ T cells in TC mice may be due a small
but significant increased frequency of cells that have lost CD62L
and/or gained CD69 expression, presumably indicating a pre-
activation status (Supplementary Fig. 1f). High mTOR expression
by TC TFH cells was confirmed by histology (Fig. 1e and Sup-
plementary Fig. 1g): TC CD4+ T cells inside GCs showed
abundant mTOR staining as compared to B6 CD4+ T cells, which
expressed mTOR in the T cell zone. STAT3 activation induces
Bcl6 expression and STAT3 deficiency impaired TFH cell differ-
entiation28–30. However, IL-21-mediated STAT3 phosphorylation
was significantly decreased in CD4+ T cells from SLE patients31.
Both young and aged TC mice showed a reduced pSTAT3
expression level in CD4+CD44+ TAct and TFH cells, but an
increased frequency of the small population of pSTAT3+ in
CD44− TN cells (Supplementary Fig. 1h, i). TC and B6 mice
showed a similar frequency of proliferating TAct and TFH cells, but
the frequency of proliferating CD44− TN cells was higher in TC
mice (Fig. 1f and Supplementary Fig. 1i). Consistent with the
higher number of CD4+ T cells in lupus mice, the number of
proliferating cells was higher for all three subsets in TC mice
(Fig. 1f and Supplementary Fig. 1j). Finally, the expression of Bcl2
at the protein (Fig. 1g) and transcript (Fig. 1h) levels was
increased in TC TFH cells. In sum, lupus TC mice show an
expansion of TFH cells that precedes the production of auto-
antibodies, and that is associated with increased mTORC1
activity and Bcl2 expression, as well as decreased STAT3 activa-
tion. This suggests that the number of TFH cells expands by
resistance to apoptosis, and possibly by an increased differentia-
tion from CD44-negative-derived precursors following an
increased proliferation and STAT3 signaling.
Glycolysis inhibition normalizes lupus TFH cells. The dual
inhibition of glycolysis and mitochondrial metabolism by the
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combination of 2DG and metformin reverses disease pathogen-
esis in TC, NZB/W F120, and B6.lpr21 lupus-prone mice. This
treatment significantly reduced anti-dsDNA IgG production, as
well as the frequency of TFH and GC B cells in these three strains,
as well as in a fourth model of lupus, the BXSB. Yaa mice, to
levels equivalent to that of B6 controls (Supplementary Fig. 2a).
The 2DG plus metformin combination also reduced Bcl6 and PD-
1 expression in total CD4+ T cells from these lupus strains
(Supplementary Fig. 2b). Although treatment with the combi-
nation of these two metabolic inhibitors is required to suppress
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clinical disease in older mice, 2DG alone is sufficient to prevent
disease development and autoantibody production21. To compare
lupus-prone strains that have a different timing of autoimmune
activation, we treated all mice starting at around 5 months of age
when they were anti-dsDNA IgG positive but without clinical
disease. After 8 weeks of treatment, 2DG reduced the production
of anti-dsDNA IgG, as well as the frequency and number of TFH
and GC B cells in these four lupus strains (Fig. 2a, b). 2DG also
reduced Bcl6 expression in both B6 and TC TFH cells (Fig. 2c) and
normalized the TFH/TFR ratio in TC mice (Fig. 2d). The addition
of metformin did not further reduce the frequency of TFH cells
(Supplementary Fig. 2c), while 2DG alone has little effect on the
frequency of TEM cells and CD69 expression in TC mice (Sup-
plementary Fig. 2d, e). 2DG reduced the number of total splenic
CD4+ T cells in all four lupus-prone strains, but not in B6 mice
(Supplementary Fig. 2f), which is consistent with CD4+ T cells
from lupus mice being glycolitic20,21. 2DG had a variable effect on
CD4+ T cell activation, decreasing the frequency of CD44+CD4+
T cells only in NZB/W F1 and BXSB.Yaa mice, but decreasing
their number in all strains 2DG, except B6.lpr mice (Supple-
mentary Fig. 2g). These results indicate that spontaneous lupus
TFH cells are uniformly sensitive to the inhibition of glycolysis
comparatively to other activated T cells that show a more variable
response among strains. CD4+ T cell effector differentiation
depends on an increased glycolysis and mTORC1 activity32.
Accordingly, 2DG reduced mTORC1 activation in both TC and
B6 TAct and spontaneous TFH cells, as well as in TC TN cells
(Fig. 2e). In addition, 2DG markedly decreased the number of
proliferating CD4+ T cells in TC mice, including TFH cells
(Fig. 2f). These results demonstrate that the expansion of spon-
taneous TFH and GC B cells and the resulting production of
autoantibodies in lupus mice depend on glycolysis and mTORC1
activation.
The TD humoral response does not require glycolysis. To
determine whether inhibiting glycolysis affects humoral immune
responses to a TD exogenous antigen, mice were immunized with
4-hydroxy-3-nitrophenylacetyl conjugated to keyhole limpet
hemocyanin (NP-KLH). We used young mice because aged TC
mice respond poorly to TD immunization33. 2DG treatment
started 2 weeks before immunization and continued for the
duration of the experiment. The primary response was analyzed
10 d after immunization and the memory response 7 weeks after
the first immunization and NP-KLH boosts at weeks 2 and 6.
2DG reduced the frequency and number of total TC GC B cells in
both primary and memory responses (Fig. 3a). However, 2DG
had no effect on the high frequency and number of TC plasma
cells (Fig. 3b), but it reduced anti-dsDNA IgG levels in TC mice
tested for the memory response (Fig. 3c). As previously repor-
ted33, the frequency and number of NP-specific GC B cells was
decreased in TC mice as compared with B6 controls in the pri-
mary response (Fig. 3d). More importantly, 2DG did not decrease
the frequency and number of these NP-specific GC B cells
(Fig. 3d). As for total plasma cells, the frequency and number of
B6
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Fig. 2 Autoreactive TFH cells are sensitive to glycolysis inhibition. Frequency (a) and cell number (b) of TFH cells (left, CD4+CXCXR5+PD1+Bcl6+Foxp3−)
in CD4+ T cells and GC B cells (middle, B220+GL7+FAS+) in B cells, as well as serum anti-dsDNA IgG (right) in four strains of lupus-prone mice treated
with 2DG for 8 weeks starting at 5–6 months of age, as compared to untreated age-matched controls. Contemporaneous untreated B6 mice are shown as
reference. Mean+ s.e.m. of N= 3–28 mice per group. c–f 3–4-month-old B6 and TC mice were treated 2DG or not for 1 month. MFI of Bcl6 in TFH cells (c)
and the ratio of TFH (CD4+CXCXR5+PD1+Bcl6+Foxp3−) to TFR (CD4+CXCXR5+PD1+Bcl6+Foxp3+) cells (d). Phospho-S6 (e) as well as frequency and
number of Ki-67+ (f) cells in TN cells (CD4+ CD44−), TAct cells (CD4+CD44+), and TFH cells (CD4+CD44+PD-1hiPSGL-1lo). Mean+ s.e.m. of N=
4–9 spleens per group compared with t tests. *P < 0.05, **P < 0.01, and ***P < 0.001
Fig. 1 Increased mTORC1 activity and survival in TC TFH cells. a–c Frequency and cell number of CD69+ (a), CD4+CD44+CD62L− TEM cells (b), and CD4
+CXCXR5+PD1+Bcl6+Foxp3− TFH (c) in CD4+ T cells, with the relative distribution of TFH and Foxp3+ TFR cells in CD4+CXCXR5+PD1+Bcl6+ cells.
d Mean fluorescence intensity (MFI) of phospho-S6 in TN cells (CD4+CD44−), TAct cells (CD4+CD44+), and TFH cells (CD4+CD44+PD-1hiPSGL-1lo).
e Representative mTOR staining (green) in the GC (plain line) and T cell zone (dashed line) relative to non-GC B cells (IgD+ red) and CD4+ T cells
(purple). Arrows point to examples of mTOR staining. Scale bars: 200 μM for 10× and 10 μM for 20×. f Frequency and number of Ki-67+ proliferating TN,
TAct, and TFH cells. g Bcl2 MFI in CD4+CXCXR5+PD1+ TFH and CD4+CXCXR5−PD1− non-TFH cells, with representative FACS plots on the left. h Bcl2
mRNA expression in TFH and non-TFH cells as determined with a Nanostring custom panel. Spleens from 9-month-old B6 and TC mice, mean+ s.e.m. of
N= 3–8 mice per group compared with t tests. *P < 0.05, **P < 0.01, and ***P < 0.001
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NP+ plasma cell was similar between 2DG-treated and control
TC and B6 mice (Fig. 3e). Furthermore, 2DG has no effect on the
number of NP-specific IgG producing cells in memory-
immunized TC mice (Fig. 3f). The levels of serum NP-specific
IgG1, which is the main isotype produced in this TD immuni-
zation, mirrored the cellular results, even with an increase of low-
affinity NP-specific memory IgG1 (Fig. 3g). 2DG tended to
decrease the level of TH1-driven NP-specific IgG2a, only observed
in the TC memory response (Fig. 3g). Overall, these results
suggest that autoreactive GCs, but not GCs induced by exogenous
Ag, are sensitive to glycolysis inhibition. The frequency and
number of total TFH cells and the ratio of TFH to TFR cells were
decreased in 2DG-treated TC mice in the primary, but not in the
memory response (Fig. 3h, i), when the frequency of NP-KLH-
specific TFH relative to spontaneous TFH cells is likely much
higher than in the primary response. Importantly, B6 TFH cells,
which contain only a small frequency of autoreactive cells, were
not affected by 2DG, suggesting that glycolysis is not necessary
for the differentiation of exogenous Ag-specific TFH cells.
Exogenous Ag-specific TFH cells do not require glycolysis. We
tested the effect of 2DG on Ag-specific TFH cells induced by a
non-lethal dose of influenza virus A/Puerto Rico/8/1934 H1N1
(PR8). Virus-specific CD4+ T cells were detected with the MHC
class II tetramer recognizing the nucleoprotein (NP) immuno-
dominant viral epitope NP311-325 (NP-Tet)34,35 10 d after
infection. Weight loss, a clinical indicator of influenza infection,
was observed in B6 mice and was enhanced by 2DG, while neither
2DG-treated nor control TC mice lost weight (Supplementary
Fig. 4a). 2DG did not affect the frequency of virus-specific CD4+
T cells (Fig. 4a), and TFH cells (Fig. 4b and Supplementary
Fig. 4b) in either strain, but the number of virus-specific TFH cells
was lower in 2DG-treated TC mice than in controls (Fig. 4b),
corresponding to a global effect of 2DG on lymphoid expan-
sion21. Both the frequency and number of total TC TFH cells,
which contain both spontaneous and virus-specific cells, were
however decreased by 2DG (Fig. 4c), as we observed with non-
immunized (Fig. 2a) and NP-KLH-immunized mice (Fig. 3h).
Furthermore, the 2DG treatment did not decrease the amount of
3 isotypes of NP-specific IgG 4 weeks after infection (Fig. 4d),
whereas it reduced anti-dsDNA IgG production in the same TC
mice (Fig. 4e). A similar pS6 expression was observed in NP-
Tetpos TFH cells between B6 and TC mice 10 d after infection
(Supplementary Fig. 4c). Unexpectedly, glycolysis inhibition
increased pS6 expression in NP-Tetneg TFH cells and there was a
similar trend for NP-Tetpos TFH cells in TC mice. This result
suggests that glycolysis is not the main pathway of mTORC1
activation during exogenous Ag-specific TFH cell differentiation.
In addition, 2DG had no effect on STAT3 activation and pro-
liferation in TFH cells (Supplementary Fig. 4d, e), except for a
small increase in the proliferation of NP-Tetneg TC TFH cells
(Supplementary Fig. 4e). Thus, these results strongly suggest that
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glycolysis is not necessary for exogenous Ag-specific TFH cell
differentiation.
We also examined the effect of 2DG on IFNγ-producing CD4+
T cells, as well as virus-specific CD8+ T cells in the lung, both of
which being critical for protection36. The number and frequency
of either total IFNγ+ or virus specific NP-TetposIFNγ+ CD4+
T cells were similar in the lung (Fig. 4f, g) and spleen
(Supplementary Fig. 4f, g) between 2DG-treated and control
TC mice. This confirms earlier results showing that metformin
but not 2DG normalizes IFNγ production in TC mice21.
Similarly, 2DG did not affect the number of NP-TetposCD8+
T cells in the lung (Fig. 4h, i) and spleen (Supplementary Fig. 4h)
of either B6 or TC mice. Interestingly, 2DG had opposite
outcomes on the type of virus-specific effector CD8+ T cells: 2DG
expanded short-lived effector cells (SLEC, KLRG1+CD127-NP-
TetposCD8+) in TC mice while it expanded memory precursor
effector cells (MPEC, KLRG1−CD127+NP-TetposCD8+) in B6
mice (Fig. 4i–k and Supplementary Fig. 4i, j) leading to opposite
SLEC/MPEC ratios between the two strains in the lung (Fig. 4l)
and a similar trend in the spleen (Supplementary Fig. 4k). These
results suggest that the inhibition of glycolysis does not prevent
the differentiation of virus-specific protective CD4+ and CD8+
T cells, but modulates the type of effector cells it produces. Virus-
induced differentiation of SLEC is favored by inflammatory
signals such as CpG and IL-1237, both of which have been
associated with lupus. How this process is enhanced by the
inhibition of glycolysis needs to be further explored.
Differential expression of solute transporters in TC TFH cells.
Based on the observation that TFH cells were more sensitive to
glycolysis inhibition than other types of activated CD4+ T cells in
TC mice (Supplementary Fig. 2c‒e), we compared the expression
of Hif1a and Mct4, two key genes in the glycolytic pathway,
between total CD4+ T cells and spontaneous TFH cells (CD4
+CXCR5+PD-1+) sorted from 8-10 month old TC mice (Sup-
plementary Fig. 5a). TC TFH cells showed a 3–5 fold increased
expression of Hif1a and Mct4 (Fig. 5a), and an increased Hif1α
protein expression (Fig. 5b) as compared to total CD4+ T cells.
Moreover, the extracellular acidification rate (ECAR), a measure
of glycolysis, was higher in TC TFH than B6 TFH cells, while
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Fig. 4 Glycolysis inhibition does not impair the humoral response to influenza immunization. 8–10-week-old B6 and TC mice were infected with PR8
influenza virus. 2DG treatment was initiated 2 weeks before infection and maintained until termination. CD4+ and CD8+ T cells were analyzed 10 d after
infection. a Representative FACS plot (left) and percentage (right) of splenic influenza virus-specific CD4+ T cells (CD4+CD44+NP-Tetpos). b, c
Frequency and number of CD4+CD44+PD-1hiPSGL-1lo TFH cells in PR8 virus-specific NP-TetposCD4+ T cells (b) and in total CD4+ T cells (c). Serum levels
of PR8 NP-specific IgG1, IgG2b and IgG2c (d), and anti-dsDNA IgG (e) 30 d after low dose infection. f, g Frequency and number of IFNγ+ in total CD4+
T cells (f) and PR8 virus-specific NP-TetposCD4+ T cells (g) in the lung. h, i Analysis of NP-TetposCD8+ T cells in the lung: representative FACS plots (h),
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CD44−CD4+ T cells were similar between the two strains
(Fig. 5c, d). Oxygen consumption rate (OCR) was similar between
B6 and TC TFH cells, (Supplementary Fig. 5b). These results
confirm that autoreactive TFH cells have a high metabolic demand
fueled through glycolysis. Glucose uptake was similar between B6
and TC TFH cells (Fig. 5e) as we have previously shown for total
CD4+ T cells20, suggesting that glucose utilization rather than
uptake distinguishes spontaneous lupus TFH cells. We next
compared gene expression between TC and B6 spontaneous TFH
cells. Among ~1100 differently expressed genes (Supplementary
Fig. 5c, d), the differentially expressed pathways confirmed the
immunophenotyping results, with greater mTOR activation,
proliferation and reduced oxidative phosphorylation in TC TFH
cells (Supplementary Fig. 5e). Although pSTAT3 levels were
decreased in TC TFH cells (Supplementary Fig. 1h, i), the IL-
6_JAK_STAT3 signaling pathway was overexpressed in TC TFH
cells, suggesting that it contributes to their expansion. Finally, the
KRAS pathway was also overexpressed in TC TFH cells.
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Fig. 5 Spontaneous TC TFH cells are glycolytic and show an altered expression of solute transporters. a Hif1a and Mct4 gene expression was compared
between total CD4+ T cells and TFH cells (CD4+CXCR5+PD-1+) from TC mice using qRT-PCR and normalized to Ppia. b Hif1α protein expression (as
determined by MFI using flow cytometry) in total CD4+ T cells and TFH cells from B6 and TC mice. c–d ECAR during a mitochondrial stress test conducted
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qRT-PCR, and normalized to Hmbs. h Representative FACS plot (left) and MFI (right) of CD98 expression on TC and B6 TFH cells. All T cells were isolated
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Interestingly, monogenic mutations in this pathway are associated
with SLE38, and KRAS is involved in CD4+ T cell activation in
patients with rheumatoid arthritis39. Among the top 10 differ-
entially expressed genes (Supplementary Fig. 5f), we noticed three
members of the solute carrier family, including the neutral amino
acid transporter Slc1a5 (Asct2), a crucial mediator of TCR-
stimulated glutamine uptake in CD4+ T cells40, that is necessary
for TH1 and TH17 cell differentiation41. A striking signature of
31 solute transporter genes characterized spontaneous lupus TFH
cells (Fig. 5f and Supplementary Table 1). qRT-PCR analysis
confirmed an increased expression of two glycolytic genes, Slc2a6
(Glut6) and Slc37a2 encoding for glucose-6-phosphate transpor-
ter in TC TFH cells (Fig. 5g). We also confirmed the elevated
expression of two amino acid transporters Slc1a4 (Asct1) and
Slc16a10 (Mct10), and the reduced expression of the amino acid
transporter Slc7a10 (Asc-1) in TC TFH cells (Fig. 5g). Slc3a2
(CD98) heterodimerizes with Slc7a5 (Lat1), Slc7a6, Slc7a7, or
Slc7a8 (Lat2) to transport hydrophobic large neutral amino
acids42,43 and kynurenine44. TC TFH cells showed a reduced
expression of CD98 (Fig. 5h), although the gene expression of
neither Slc3a2 nor Slc7a5 showed a difference in the microarray
analysis. Taken together, these results suggest that autoreactive
TFH cells have different metabolic requirements for amino acids
and in the glucose pathway.
Spontaneous and Ag-specific TFH cells require glutamine. To
further compare gene expression between TC and B6 TFH cells, we
selected a NanoString panel of 100 genes related to TFH cell dif-
ferentiation, CD4+ T cell function and metabolism (Supplementary
Table 2) to probe a new set of spontaneous TC and B6 TFH cells.
We identified a signature of 10 genes that differentiated TC from
B6 spontaneous TFH cells in both the microarray and Nanostring
results (Fig. 6a). Slc1a5 expression was reduced in TC spontaneous
TFH cells (Fig. 6a, b) and NP-Tetneg TC TFH cells (Fig. 6c).
Importantly, B6 and TC influenza virus-specific NP-Tet+ TFH cells
showed a similar level of Slc1a5 expression (Fig. 6c). CD98
expression was also similar in NP-Tetpos TC and B6 TFH cells, but
lower in TC than B6 NP-Tetneg TFH cells (Fig. 6d). Slc1a5 is the
major glutamine transporter, and CD98 also acts as a glutamine
transporter in TCR-stimulated CD4+ T cells. Since Slc7a5 deletion
in CD4+ T cells results in a defective TD-response33, we hypo-
thesized that exogenous Ag-induced TFH cells require glutamine
metabolism. We thus tested whether blocking glutaminolysis with
DON inhibited the humoral response to NP-KLH primary
immunization (Fig. 7a). DON had no effect on the frequency and
number of total CD4+ T cells in immunized B6 and TC mice
(Supplementary Fig. 6a). However, DON reduced the frequency of
TEM cells in immunized mice from both strains, and the frequency
of CD69+CD4+ T cells in immunized TC mice (Supplementary
Fig. 6b, c). Neither the frequency or number of TFH cells, or the
TFH/TFR ratio were affected by DON treatment (Fig. 7b, c). How-
ever, the expression of Bcl6, CD40L and ICOS was decreased in the
TFH cells of DON-treated mice in both strains (Fig. 7d). This
suggests that glutaminolysis is required for optimal Tfh cell function
and interaction with GC B cells. In addition, DON reduced the
frequency of TH17 and TH1 cells but not the frequency of IL-10-
producing CD4+ T cells in immunized TC and B6 mice (Supple-
mentary Fig. 6d), which is consistent with results obtained with
Sle1a5-deficient T cells43. DON treatment of immunized mice had
little effect on total B cells (Supplementary Fig. 6e), but it decreased
the frequency and number of GC B cells (Supplementary Fig. 6f), as
well as the size of GCs and their GL7 expression (Fig. 7e and
Supplementary Fig. 6g). The few GCs found in the spleens of DON-
treated mice were very small with very few B cells. Accordingly, the
frequency and number of Ag-specific GC B cells (Fig. 7f), although
not plasma cells (Fig. 7g), were severely reduced by DON treatment.
Accordingly, levels of NP-specific IgG1 and IgM were lower in
DON-treated B6 and TC mice (Fig. 7h). The frequency of total
plasma cells was reduced by DON only in TD-immunized TC mice
(Supplementary Fig. 6h). Furthermore, DON reduced the level of
total serum IgM in TD-immunized mice from both strains, but
reduced the level of total IgG only in TD-immunized B6 mice
(Fig. 7i). The serum of TD-immunized TC mice contains a mixture
of autoantibodies and NP-KLH-induced IgG, while the serum of
B6-immunized mice contains a greater relative amount of anti-NP-
KLH antibodies. Taken together, these results strongly suggest that
exogenous Ag-specific GC responses require glutamine metabolism.
GCs form 4–5 d after antigen activation and GC maturation is
fully achieved at 7 d45. Therefore, we treated B6 and TC mice
with DON at 5 and 7 d after NP-KLH immunization
(Supplementary Fig. 7a) to test the proximal effect of glutami-
nolysis inhibition on GC development. DON reduced the
frequency but not the number of total B cells in immunized
mice from both strains; however, the frequency and number of
total and Ag-specific GC B cells or plasma cells were not affected
by the treatment (Supplementary Fig. 7b-e). Similar results were
obtained with total CD4+ T cells and TFH cells (Supplementary
Fig. 7f, g). As with the continuous DON treatment during
immunization (Fig. 7d), Bcl6 expression was decreased in TFH
cells in DON-treated B6 mice and there was a trend for TC mice
(Supplementary Fig. 7h). Despite this modest effect, if any, of
targeted DON treatment on either GC B cells or TFH cells, the
production of NP-specific IgG1 and IgM (Supplementary Fig. 7i)
was markedly decreased in DON-treated mice from both strains.
Finally, we investigated the effect of a 2-week-long DON
treatment on spontaneous GCs formation and anti-dsDNA IgG
secretion in 7–8-month-old B6 and TC mice. DON reduced the
frequency and number of TC B cells and GC B cells in both
strains (Fig. 8a, b), but it did not affect splenic plasma cells
(Fig. 8c). The size, number and GL7-staining intensity of GCs
were greatly reduced by DON in both stains (Fig. 8d, e). DON
treatment also normalized the size of the follicles in TC mice
(Fig. 8d, f), which corresponds to a combined decreased
number of B cells (Fig. 8a) and CD4+ T cells (Fig. 8g). The
frequency TFH cells was not affected by DON, but the number
of TFH cells was reduced to B6 levels in DON treated TC mice
(Fig. 8h), and they expressed a lower level of Bcl6 (Fig. 8i).
Finally, the production of anti-dsDNA IgG was reduced in both
strains (Fig. 8j), although from a much lower level in B6 mice.
The potential therapeutic effect of DON on renal pathology
could not be examined due to the short duration of the
treatment. Taken together, these results indicate that both Ag-
specific and spontaneous GC formation as well as the resulting
antigen-specific Ab and autoantibodies are sensitive to the
inhibition of glutamine metabolism. Similarly, both antigen-
specific and spontaneous GC B cells and TFH cells require
glutamine, although to a lesser extend for TFH cells.
Discussion
We show here that the expansion of TFH cells reported in SLE
patients and in lupus-prone mice4 occurs early before disease
manifestation. The frequency of TFH cells is twice higher in pre-
autoimmune TC mice as compared to B6 mice, further sup-
porting a causative role. Therapeutic targeting of TFH cells has
been proposed for SLE patients46,47. In addition to their direct
effect on autoantibody production, IL-21 impairs human Treg
cells from SLE patients in association with mTOR activation48.
Therefore reducing the number of lupus TFH cells may have the
added benefit of enhancing Treg number and functions. The
mechanisms responsible for the expansion of TFH cells in lupus
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are poorly understood46. We show here that the expansion of TFH
cells in lupus-prone TC mice is associated with an increased
expression of Bcl2. Proliferation and STAT3 signaling were
similar between TC and B6 TFH cells, but increased in naive TC
CD4+ T cells, in which glycolysis is also higher than in naive B6
CD4+ T cells20. These findings suggest a model in which the
accumulation of TFH cells in TC mice results from the combi-
nation of an accelerated induction in proliferating glycolytic naive
CD4+ T cells in which STAT3 is activated, possibly in response to
the high level of IL-6 present in these mice49–51, and a resistance
to apoptosis.
Immune cells, and T cells in particular, are functionally regu-
lated by their metabolic substrate utilization52, and alterations in
the metabolism of immune cells have been reported in lupus17,18.
A combination of two metabolic inhibitors, metformin, which
targets mitochondrial respiration, and 2DG, an inhibitory glucose
analog, has therapeutic effects in vivo in mice and in vitro with
human SLE CD4+ T cells20,21. In this study focused on Tfh cells
instead of clinical outcomes, we show that inhibiting glycolysis is
sufficient to reverse the expansion of TFH cells in four different
models of lupus, with a concomitant reduction of GC B cell
expansion and anti-dsDNA IgG production. Glucose inhibition
reduces mTORC1 activation, which may be responsible for the
reduction in Bcl6 levels in these TFH cells. The dramatic response
of lupus TFH cells to 2DG while reducing the frequency of TEM
cells requires the combination of 2DG and metformin (21 and this
study) indicate that lupus TFH cells have a greater glucose
requirement than other activated effector CD4+ T cells. A
recently completed clinical trial for sirolimus in SLE patients
showed that mTOR inhibition decreased the frequency of per-
ipheral CD8+ TEM cells in responsive patients53. Since mTOR
activation and glycolysis are tightly linked, it is likely that gly-
colysis contributes at least in part to the expansion of these CD8+
TEM cells, and their novel predictive value warrants further
examination in lupus mice.
An effective and safe therapy in SLE should target the TFH cells
that drive the production of pathogenic autoantibodies without
affecting TFH cells responding to pathogens. We used two dif-
ferent models to address the impact of glucose inhibition on TFH
cells induced by exogenous antigens. NP-KLH immunization
does not address directly the glucose requirements of Ag-specific
TFH cells, but class-switched high affinity NP-antibodies are
clearly TFH-dependent. In both primary and memory responses,
glucose inhibition does not impair the generation of NP-specific
GC B cells and anti-NP IgG, while it eliminates anti-dsDNA IgG
in the same mice. The influenza virus infection model confirms
that the induction of Ag-specific TFH cells is not impaired by
2DG, and that 2DG-treated TFH cells fully support the production
of flu-specific antibodies, while again, in the same mice, anti-
dsDNA IgG levels are reduced. Therefore, these results suggest
that glucose inhibition can eliminate autoreactive TFH cells while
preserving the ability to mount a protective response to patho-
gens. Selective targeting of pathogenic autoreactive immune cells
has been an elusive goal in lupus and other autoimmune diseases.
Our results suggest that this could be achieved though the tar-
geting of T cell metabolism.
We propose a model in which all TFH cells, especially those
induced by exogenous antigens, require glutamine and sponta-
neous autoreactive TFH cells are uniquely glycolytic (Supple-
mentary Fig. 8). This model is supported by the differential
expression of solute transporters favoring amino acid flux in
spontaneous B6 TFH cells and glucose flux in TC TFH cells.
Moreover, the expression of amino acid transporters Slc1a5 and
CD98 is reduced in spontaneous TC TFH cells but not in virus-
specific TFH cells. Finally, the glutamine inhibitor DON prevents
the production of NP-specific IgG, but maintains total IgG levels
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in TC mice, suggesting a preferential requirement for glutamine
in Ag-induced TFH cells. In addition to being an effective T cell
inhibitor in alloreactive responses54, we show here that DON
inhibits Ag-specific TFH cells. mTORC1 is activated in T cells
either by TCR/PI3K/AKT signaling or amino acid uptake55,
specifically through CD9833. The low CD98 expression in spon-
taneous TC TFH cells suggests that their high mTORC1 activation
is fueled by the PI3K/AKT axis, which in turn enhances glyco-
lysis. On the other hand, our results suggest that CD98 mediated
mTORC1 activation is required for the induction of Ag-specific
TFH cells. mTORC1 activation is necessary in TFH cells25,26, and it
promotes Bcl6 translation in autoreactive TFH cells27, which is
consistent with high mTORC1 activation in spontaneous lupus
TFH cells. PR8 virus-induced TFH cells present however a similar
level of mTORC1 between lupus and control mice, which is
consistent with the relatively low level of mTORC1 activation that
was reported in LCMV-induced TFH cells22. The elucidation of
the mechanisms of mTORC1 activation in autoreactive sponta-
neous vs. Ag-induced TFH cells will be critical to understand in
their function.
The different metabolic requirements of spontaneous auto-
reactive and Ag-induced TFH cells imply that these two types of
TFH cells are qualitatively different, either in their differentiation
or function. Spontaneous GC B cells have unique intrinsic
requirements for IFNγ and IL-6 signaling in two different auto-
reactive models56,57. The differential response of spontaneous and
Ag-induced GC B cells to 2DG mirrored the response of the
corresponding TFH cells in TC mice. Both spontaneous and
induced GC B cells were however sensitive to glutamine inhibi-
tion. The development and maintenance of TFH and GC B cells
are tightly linked and the treatment with 2DG could affect
directly both cell types. Very little is known on GC B cell meta-
bolism, except that, as TFH cells, GC B cells induced upon
immunization require intrinsic mTORC1 activation58,59. In
addition, treatment with rapamycin during influenza infection
alters affinity maturation of virus-specific antibodies60. mTORC1
is also necessary for optimal antibody synthesis in long-lived
plasma cells suggesting diverse roles of mTOR in humoral
immunity61. Our results suggest either that autoreactive or Ag-
induced GC B cells have different metabolic requirements, or that
their differential response to 2DG and DON is a consequence of
the effect that these inhibitors have on TFH cells. An expansion of
circulating TFH cells has been reported in multiple autoimmune
diseases besides SLE62. Further investigation of the metabolic
requirements of TFH and GC B cells in these autoimmune con-
ditions relative to pathogen exposure should advance the quest
for targeted therapeutics in autoantibody-mediated autoimmune
diseases as well as our understanding of the mechanisms by
which autoreactive GCs are generated and maintained.
Methods
Mice and treatment of metabolic inhibitors. C57BL/6J (B6), NZB/W F1, B6.
MRL-Faslpr/J (B6.lpr) and BXSB.Yaa mice were originally obtained from the
Jackson Laboratory. B6.NZM-Sle1NZM2410/AegSle2NZM2410/AegSle3NZM2410/Aeg/
LmoJ (TC) congenic mice have been previously described19. All mice were bred
and maintained at the University of Florida and Jackson Laboratories (BXSB.Yaa)
in specific pathogen-free conditions. For in vivo metabolic inhibitor treatments,
2DG (Sigma, 6 mg/ml) or metformin (Sigma, 3 mg/ml) were dissolved in drinking
water, and mice received 2DG alone or the combination of the two drugs for the
duration indicated for each study. Age-matched control mice receiving plain
drinking water were used as controls. DON (1.6 mg/kg) was administered intra-
peritoneally every other day for a maximum of 2 weeks. For spontaneous GC
formation, lupus-prone mice were first screened for serum anti-dsDNA IgG levels
between 5 and 6 months of age. Anti-dsDNA IgG-positive mice (i.e., >+2 SD than
the average for age-matched B6 controls) were assigned to treated or control
groups to distribute equally the autoantibody levels. Only female mice at the age
indicated for each experiment were used in this study under protocols approved by
the Institutional Animal Care and Use Committees of the University of Florida and
the Jackson Laboratory.
Flow cytometry and immufluorescence staining. Single-cell suspensions were
prepared from spleens using standard procedures. Lungs from PR8-virus infected
mice were processed with LiberaseTL (Sigma)63. After red blood cell lysis, cells
were blocked with anti-CD16/32 Ab (2.4G2), and stained in FACS staining buffer
(2.5% FBS, 0.05% sodium azide in PBS). Fluorochrome-conjugated Abs used for
FASC are listed in Supplementary Table 3. Follicular T cells were stained in a three-
step process using purified CXCR5 (2G8) followed by biotinylated anti-rat IgG
(Jackson ImmunoResearch Laboratory) then PerCP-labeled streptavidin in FACS
staining buffer on ice. For the intracellular staining, cells were fixed and permea-
bilized with Foxp3 stating buffer (Thermo Fisher) according to the manufacturer’s
protocol. 4-Hydroxy-3-nitrophenylacetyl (NP)-Phycoerythrin was purchased from
Biosearch Technology. Dead cells were excluded with fixable viability dye
(eFluor780; Thermo Fisher). Data were collected on LSRFortessa (BD Biosciences)
and analyzed with FlowJo software (Tree Star). To measure glucose uptake, sple-
nocytes were stained with subset-specific antibodies, then resuspended in PBS with
1 μM 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2NBDG;
Life Technologies) for 15 min. After twice washing, cells were analyzed for 2NDBG
uptake using flow cytometry. Immunofluorescence staining of spleen frozen sec-
tions was performed with an mTOR polyclonal antibody (PA5-34663, 1:1000
dilution) followed by an Alexa Fluor 594-conjugated donkey anti-rabbit IgG (A-
2107, 1:200 dilution), both from Thermo-Fisher. GCs were stained with anti-GL7-
FITC (LY-77; 1:25), B cells with anti-IgDb-PE (217-170, 1:50) and CD4+ T cells
with anti-CD4-APC (RM4-5, 1:100), all from BD Bioscience.
TD Immunization, ELISA, and ELISPOT. For NP-KLH immunization, 8–10-
week-old mice were pretreated 2DG for 2 weeks before receiving an intra-
peritoneal injection of a 100 μg NP(31)-KLH (Biosearch Technology) in alum. The
primary response was analyzed 10 d after immunization, and the recall response
was analyzed 7 weeks after the first immunization after boosting with same Ag at
weeks 2 and 6. To analyze glutamine metabolism in the primary TD response,
DON (1.6 mg/kg, Sigma-Aldrich) was administered intra-peritoneally every other
day starting on the day of immunization with NP-KLH, or at days 5 and 7. Serum
NP-specific antibodies were measured by ELISA using plates coated with NP(4)- or
NP(25)-BSA (high or low affinity, respectively) (Biosearch Technology), followed
by incubation with 1:1000 diluted serum samples, and developed with alkaline
phosphatase-conjugated goat anti-mouse IgG1 (1071-04, 1:1000) or IgG2a (1071-
04, 1:1000), both from Southern Biotech. All samples were run in duplicate. Anti-
dsDNA IgG were measured in sera diluted 1:100 in plates coated with 50 ug/ml
dsDNA. Bound IgG was detected using alkaline phosphatase-conjugated anti-
mouse IgG (115-055-003, Jackson ImmunoResearch) diluted 1:1000. Relative units
were standardized using serial dilutions of a positive serum from TC mice, setting
the 1:100 dilution reactivity to 100 U64. Spleen antibody-secreting cells were
quantified by an NP-specific IgG ELISPOT assay on serially diluted splenocytes
using 96-well mixed cellulose esters membrane plates (Millipore) coated with 50
μg/ml NP(25)-BSA35. Bound cells were detected with HRP‐conjugated‐anti‐IgG
(1036-05, Southern Biotech) at 1:1000 dilution, and developed by 3‐amino‐9‐
ethylcarbazole (Sigma‐Aldrich). Antibody-secreting cells were then counted and
measured using a Bioreader 4000 Pro‐x (Bio‐Sys). Germinal center imaging was
performed on frozen sections from spleens collected 10 d after immunization.
Influenza virus infection. Influenza A virus strain A/Puerto Rico/8/1934 H1N1
(PR8) was kindly provided by Paul G. Thomas (St. Jude Children’s Research
Hospital). Infection with PR8 virus was carried out on 8–10 week old 2two weeks
after treatment with 2DG started. A volume of 30 μl of HBSS containing 1 × 102
PFU (immunization low dose) or 1 × 106 PFU (challenge high dose) of PR8 virus
were inoculated intranasally (i.n.) in mice anesthetized with isoflurane. To detect
virus-specific CD4+ T cells and CD8+ T cells, fluorescence-conjugated MHC-II
and MHC-I peptide tetramers, respectively, were obtained from the National
Institutes of Health Tetramer Core facility (Emory University, Atlanta, GA). After
single cell suspensions (5 × 106 cells) were stained with CD4+ T cell antibodies,
then incubated with 30 μg/ml of influenza A nucleoprotein (NP) peptide (311-325,
QVYSLIRPNENPAHK) I-Ab tetramers for 2 h at 37 °C in a 5% CO2 atmosphere.
Virus specific CD8+ T cells were detected with NP peptide (366–374, ASNEN-
METM) H-2Db tetramers. To test the protective effect of serum from immunized
mice, cohorts of B6 and TC mice were treated or not with 2DG. Two weeks later,
all mice were infected i.n. with a low dose of PR8 virus. 3 weeks later, mice were
sacrificed, immune sera were collected. 150 μl of 2DG serum or control serum was
transferred intra-peritoneally into naive B6 recipients. One day after transfer, mice
were infected i.n. with a high dose of PR8 virus. Naive mice that did not receive
serum were used as negative controls for protection and mice that were originally
immunized intra-nasally were used as positive controls for protection. Animals
were weighed daily and mean percent of initial body weight was calculated for each
group. Influenza A NP-specific antibodies were measured in serum collected 30 d
after low dose immunization by ELISA. Plates were coated with 100 μl of recom-
binant NP at 1 μg/ml (Novus Biologicals), followed by incubation with serial
dilutions of serum samples (50, 100, 200, 400, 800, and 1600) and developed with
alkaline phosphatase-conjugated goat anti-mouse IgG1 (1071-04), IgG2b (1091-
04), and IgG2c (1078-04, all from Southern Biotech) each at 1:1000 dilution. The
optimal serum dilution to show differences between groups was determined to be
1:200. All samples were run in duplicate.
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Gene expression. TFH cells (CD4+PD-1+CXCR5+) sorted from 8–10-month-old
mice were pooled to generate 5 TC and 3 B6 samples. Total RNA was extracted
with RNeasy Mini kit (Qiagen). 200 ng of total RNA per sample was used to
generate labeled cDNA fragments with GeneChipTM WT cDNA Labeling Kit
(Thermo Fisher) that were hybridized to Affymetrix MTA 1.0 microarrays
(Thermo Fisher) with Thermo Fisher reagents. Microarrays were processed with
the GeneChip 3000 7G scanner and GeneChip Fluidics Station 450 (Thermo
Fisher). Raw CEL files were normalized by the RMA algorithm with Partek
Genomic Suite 6.6 (Partek). SYBR green (Biorad)-based qPCR was performed on
cDNA synthesized from sorted T cell subsets with primer sequences shown in
Supplementary Table 4. Normalization to housekeeping genes Hmbs or Ppia was
carried out with the 2−ΔΔCt method. A custom nCounter Gene Expression CodeSet
panel (Supplementary Table 2) was generated by NanoString Technology. Using
50 ng of total RNA per sample, cartridge preparation and scanning was carried out
according to manufacturer’s instructions using the NanoString Prep Station and
nCounter Digital Analyzer. Data was analyzed with nSolver Analysis software,
version 2.5 with normalization utilizing positive and negative control probes as well
as housekeeping genes.
Statistical analysis. Differences between groups were evaluated by two-tailed
statistics: unpaired t tests or Mann–Whitney U tests depending on whether the data
were normally distributed, and two-way ANOVA tests for time-course experiments.
Unless specified, graphs show means and standard error of the mean (s.e.m.).
Data availability
Microarray data shown in this study have been deposited in the Gene Expression
Omnibus (GEO) database with accession GSE106455. The authors declare that all other
data supporting the findings of this study are available within the paper and its Sup-
plementary Information files.
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